CA3166251A1 - Compounds for the treatment of myelofibrosis - Google Patents

Compounds for the treatment of myelofibrosis

Info

Publication number
CA3166251A1
CA3166251A1 CA3166251A CA3166251A CA3166251A1 CA 3166251 A1 CA3166251 A1 CA 3166251A1 CA 3166251 A CA3166251 A CA 3166251A CA 3166251 A CA3166251 A CA 3166251A CA 3166251 A1 CA3166251 A1 CA 3166251A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
administered
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166251A
Other languages
English (en)
French (fr)
Inventor
Francis J. Giles
Andrew Mazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actuate Therapeutics Inc
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of CA3166251A1 publication Critical patent/CA3166251A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3166251A 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis Pending CA3166251A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
US62/953,654 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
CA3166251A1 true CA3166251A1 (en) 2021-07-01

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3166251A Pending CA3166251A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Country Status (11)

Country Link
US (1) US20230062278A1 (https=)
EP (1) EP4081213A1 (https=)
JP (1) JP2023508491A (https=)
KR (1) KR20230005808A (https=)
CN (1) CN115697323A (https=)
AU (1) AU2020415440A1 (https=)
BR (1) BR112022012819A2 (https=)
CA (1) CA3166251A1 (https=)
IL (1) IL294369A (https=)
MX (1) MX2022008046A (https=)
WO (1) WO2021133866A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
CN112351819B (zh) * 2018-06-05 2023-11-10 开动疗法公司 治疗恶性淋巴增生性疾病的方法

Also Published As

Publication number Publication date
CN115697323A (zh) 2023-02-03
BR112022012819A2 (pt) 2022-09-06
IL294369A (en) 2022-08-01
JP2023508491A (ja) 2023-03-02
MX2022008046A (es) 2022-11-14
WO2021133866A1 (en) 2021-07-01
EP4081213A1 (en) 2022-11-02
US20230062278A1 (en) 2023-03-02
AU2020415440A1 (en) 2022-08-04
KR20230005808A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
Frei et al. High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity
JP5612482B2 (ja) 癌の処理のためのγ−セクレターゼインヒビターの使用
EP3755324B1 (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
UA125216C2 (uk) Комбінована терапія
EP2885003B1 (en) Combination of pi3k inhibitor and c-met inhibitor
US20140113930A1 (en) Therapeutic combination for cancer treatment
EA028414B1 (ru) Лечение рака ингибиторами tor киназы
CN103764144A (zh) Pi3k抑制剂与mek抑制剂的协同组合
CN114246864B (zh) Csf1r激酶抑制剂及其用途
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
JP2022502492A (ja) 骨髄増殖性疾患の治療法
Rui et al. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis
CA3213359A1 (en) Alk-5 inhibitors and uses thereof
US20230062278A1 (en) Compounds for the treatment of myelofibrosis
CN112121052B (zh) 丙烯酰基苯并氮杂䓬类化合物在制备防治血液肿瘤药物中的用途
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
IL300605A (en) Combined treatments with OLIG2 inhibitors
US20240165113A1 (en) Methods of treatment for leukemia
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
TW202521118A (zh) 治療alk陽性或ros1陽性的非小細胞肺癌的方法
JP2025505381A (ja) フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物
EA051859B1 (ru) Способы лечения миелопролиферативных расстройств
HK1193045B (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226